# NCT02099058 (NCT02099058)

> A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02099058
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AbbVie
- Conditions: Advanced Solid Tumors Cancer
- Interventions: Osimertinib; Nivolumab; Telisotuzumab vedotin; Telisotuzumab vedotin; Erlotinib
- Enrollment: 237
- Primary outcome: Number of Participants with Adverse Events
- Primary outcome: Recommended Phase 2 Dose (RPTD) of ABBV-399 when Administered as Monotherapy and in Combination with Osimertinib, Erlotinib or Nivolumab
- Primary outcome: Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t)
- Primary outcome: Maximum observed plasma concentration (Cmax)
- Primary outcome: Time to Cmax (Tmax)
- Primary outcome: Terminal elimination half life

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02099058